1. Home
  2. MBIN vs XERS Comparison

MBIN vs XERS Comparison

Compare MBIN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merchants Bancorp

MBIN

Merchants Bancorp

N/A

Current Price

$49.51

Market Cap

2.3B

Sector

Finance

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$17.03

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBIN
XERS
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.8B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
MBIN
XERS
Price
$49.51
$17.03
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
★ $67.00
$17.29
AVG Volume (30 Days)
115.6K
★ 3.0M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 0.88%
N/A
EPS Growth
N/A
★ 100.00
EPS
★ 4.79
N/A
Revenue
N/A
★ $49,590,000.00
Revenue This Year
$10.52
$37.58
Revenue Next Year
$3.15
$31.16
P/E Ratio
$10.44
★ N/A
Revenue Growth
N/A
★ 142.67
52 Week Low
$30.95
$5.25
52 Week High
$56.87
$17.28

Technical Indicators

Market Signals
Indicator
MBIN
XERS
Relative Strength Index (RSI) 39.73 81.73
Support Level $47.81 $5.90
Resistance Level $51.01 N/A
Average True Range (ATR) 1.40 0.71
MACD -0.36 0.20
Stochastic Oscillator 3.97 95.37

Price Performance

Historical Comparison
MBIN
XERS

About MBIN Merchants Bancorp

Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: